Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial.
Mitchell P, Holz FG, Hykin P, Midena E, Souied E, Allmeier H, Lambrou G, Schmelter T, Wolf S; ARIES study investigators. Mitchell P, et al. Among authors: allmeier h. Retina. 2021 Sep 1;41(9):1911-1920. doi: 10.1097/IAE.0000000000003128. Retina. 2021. PMID: 33782365 Free PMC article. Clinical Trial.
Association Between Visual Acuity and Fluid Compartments with Treat-and-Extend Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: An ARIES Post Hoc Analysis.
Chaudhary V, Holz FG, Wolf S, Midena E, Souied EH, Allmeier H, Lambrou G, Machewitz T, Mitchell P; ARIES study investigators. Chaudhary V, et al. Among authors: allmeier h. Ophthalmol Ther. 2022 Jun;11(3):1119-1130. doi: 10.1007/s40123-022-00491-1. Epub 2022 Mar 18. Ophthalmol Ther. 2022. PMID: 35303285 Free PMC article.
XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration.
Korobelnik JF, Chaudhary V, Mitchell P, Kang SW, Tadayoni R, Allmeier H, Lee J, Zhang X, Machewitz T, Bailey C. Korobelnik JF, et al. Among authors: allmeier h. Ophthalmol Ther. 2024 Mar;13(3):725-738. doi: 10.1007/s40123-023-00867-x. Epub 2024 Jan 10. Ophthalmol Ther. 2024. PMID: 38198053 Free PMC article.
Real-World Management of Macular Edema Secondary to Retinal Vein Occlusion with Intravitreal Aflibercept: 24-month Results from the AURIGA Observational Study.
Giocanti-Aurégan A, Donati S, Hoerauf H, Allmeier H, Rittenhouse KD, Machewitz T, Yang CH; AURIGA Study Investigators. Giocanti-Aurégan A, et al. Among authors: allmeier h. Ophthalmol Ther. 2024 Jan;13(1):179-203. doi: 10.1007/s40123-023-00830-w. Epub 2023 Nov 4. Ophthalmol Ther. 2024. PMID: 37924481 Free PMC article.
Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema in Routine Clinical Practice: Results from the 24-Month AURIGA Observational Study.
Donati S, Yang CH, Xu X, Mura M, Giocanti-Aurégan A, Hoerauf H, Allmeier H, Machewitz T, Johnson KT, Santoro E; AURIGA study investigators. Donati S, et al. Among authors: allmeier h. Ophthalmol Ther. 2024 Jan;13(1):161-178. doi: 10.1007/s40123-023-00829-3. Epub 2023 Nov 4. Ophthalmol Ther. 2024. PMID: 37924483 Free PMC article.
13 results